Related Experiment Video

Updated: Jul 18, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Protein kinase inhibitors

I Shchemelinin1, L Sefc, E Necas

  • 1Institute of Pathological Physiology and Centre of Experimental Haematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. ishch@lf1.cuni.cz

Folia Biologica
|November 23, 2006
PubMed

Insights

Protein kinases are key targets for treating diseases, especially cancers. Developing small molecule inhibitors that target the ATP-binding site offers new hope for effective, non-invasive cancer therapies.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Protein kinases play crucial roles in cellular processes.
  • Dysregulation of protein kinases is implicated in numerous diseases, particularly malignancies.
  • Protein kinases are recognized as significant therapeutic targets for disease intervention.

Purpose of the Study:

  • To review the development and therapeutic potential of protein kinase inhibitors.
  • To highlight the significance of targeting protein kinases in medicine, especially in oncology.

Main Methods:

  • Review of existing literature on protein kinase inhibitors.
  • Analysis of small molecule inhibitors targeting the ATP-binding site of protein kinases.
  • Examples of clinically approved and investigational kinase inhibitors.

Main Results:

  • Numerous low molecular weight protein kinase inhibitors have been designed.
  • Many inhibitors compete with ATP for the ATP-binding site.
  • Several inhibitors, such as imatinib mesylate, flavopiridol, roscovitine, erlotinib, and gefitinib, are in clinical trials or approved treatments.

Conclusions:

  • Targeting protein kinases represents a promising therapeutic strategy.
  • The discovery of protein kinase inhibitors heralds a new era in medicine, particularly in non-invasive cancer treatment.
  • Protein kinase inhibitors offer new hope for effective cancer therapies.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...